Plasma Sphingomyelins in Late-Onset Alzheimer's Disease

被引：8

作者：

Fote, Gianna ^{[1
]}

Wu, Jie ^{[1
,2
]}

Mapstone, Mark ^{[3
]}

Macciardi, Fabio ^{[4
]}

Fiandaca, Massimo S. ^{[5
,6
,7
]}

Federoff, Howard J. ^{[3
]}

机构：

[1] Univ Calif Irvine, Dept Biol Chem, Irvine, CA 92717 USA

[2] Univ Calif Irvine, Ctr Complex Biol Syst, Irvine, CA USA

[3] Univ Calif Irvine, Dept Neurol, Irvine, CA 92717 USA

[4] Univ Calif Irvine, Dept Psychiat & Human Behav, Irvine, CA 92717 USA

[5] Univ Calif Irvine, Dept Neurol, Translat Lab & Biorepository, Sch Med, Irvine, CA 92717 USA

[6] Univ Calif Irvine, Sch Med, Dept Neurol Surg, Irvine, CA 92717 USA

[7] Univ Calif Irvine, Dept Anat & Neurobiol, Sch Med, Irvine, CA 92717 USA

来源：

JOURNAL OF ALZHEIMERS DISEASE | 2021年 / 83卷 / 03期

关键词：

Alzheimer's disease; metabolomics; plasma; sphingolipids; sphingomyelin; MILD COGNITIVE IMPAIRMENT; SPHINGOLIPID METABOLISM; GENETIC-VARIATION; BRAIN; CERAMIDE; RISK; ASSOCIATION; PROTEIN; HIPPOCAMPUS; PROGRESSION;

D O I：

10.3233/JAD-200871

中图分类号：

Q189 [神经科学];

学科分类号：

071006 ;

摘要：

Background: Altered plasma levels of sphingolipids, including sphingomyelins (SM), have been found in mouse models of Alzheimer's disease (AD) and in AD patient plasma samples. Objective: This study assesses fourteen plasma SM species in a late-onset AD (LOAD) patient cohort (n = 138). Methods: Specimens from control, preclinical, and symptomatic subjects were analyzed using targeted mass-spectrometrybased metabolomic methods. Results: Total plasma SM levels were not significantly affected by age or cognitive status. However, one metabolite that has been elevated in manifest AD in several recent studies, SM OHC14:1, was reduced significantly in pre-clinical AD and MCI relative to normal controls. Conclusion: We recommend additional comprehensive plasma lipidomics in experimental and clinical biospecimens related to LOAD that might advance the utility of plasma sphingomyelin levels in molecular phenotyping and interpretations of pathobiological mechanisms.

引用

页码：1161 / 1171

页数：11

共 50 条

[1] Plasma cholesterol and risk for late-onset Alzheimer's disease
Cedazo-Minguez, Angel
Ismail, Muhammad-Al-Mustafa
Mateos, Laura
[J]. EXPERT REVIEW OF NEUROTHERAPEUTICS, 2011, 11 (04) : 495 - 498
[2] The genetics of late-onset Alzheimer's disease
Myers, AJ
Goate, AM
[J]. CURRENT OPINION IN NEUROLOGY, 2001, 14 (04) : 433 - 440
[3] Cannabinoids in Late-Onset Alzheimer's Disease
Ahmed, A. I. A.
van der Marck, M. A.
van den Elsen, G. A. H.
Rikkert, M. G. M. Olde
[J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2015, 97 (06) : 597 - 606
[4] Late-Onset Alzheimer Disease
Pierce, Aimee L.
Bullain, Szofia S.
Kawas, Claudia H.
[J]. NEUROLOGIC CLINICS, 2017, 35 (02) : 283 - +
[5] Heritability of plasma amyloid β in typical late-onset Alzheimer's disease pedigrees
Ertekin-Taner, N
Graff-Radford, N
Younkin, LH
Eckman, C
Adamson, J
Schaid, DJ
Blangero, J
Hutton, M
Younkin, SG
[J]. GENETIC EPIDEMIOLOGY, 2001, 21 (01) : 19 - 30
[6] Plasma β-amyloid as a surrogate genetic marker in late-onset Alzheimer's disease
Ertekin-Taner, N
Graff-Radford, N
Younkin, LH
Eckman, C
Adamson, J
Schaid, DJ
Blangero, J
Hutton, M
Younkin, SG
[J]. ALZHEIMER'S DISEASE: ADVANCES IN ETIOLOGY, PATHOGENESIS AND THERAPEUTICS, 2001, : 303 - 310
[7] Late-onset autosomal dominant Alzheimer's disease
Hancock, P.
Larner, A. J.
[J]. EUROPEAN JOURNAL OF NEUROLOGY, 2007, 14 : 187 - 188
[8] LINKING Aβ AND TAU IN LATE-ONSET ALZHEIMER'S DISEASE
Small, S. A.
[J]. GERONTOLOGIST, 2009, 49 : 143 - 143
[9] Etiology and Pathogenesis of Late-Onset Alzheimer's Disease
Balin, Brian J.
Hudson, Alan P.
[J]. CURRENT ALLERGY AND ASTHMA REPORTS, 2014, 14 (03)
[10] Molecular genetics of late-onset Alzheimer's disease
Kamboh, MI
[J]. ANNALS OF HUMAN GENETICS, 2004, 68 : 381 - 404

← 1 2 3 4 5 →